Trials / Completed
CompletedNCT04763226
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986308 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986308 | Specified dose on specified days |
| OTHER | Placebo (for BMS-986308) | Specified dose on specified days |
| DRUG | Furosemide | Specified dose on specified days |
Timeline
- Start date
- 2021-04-14
- Primary completion
- 2022-02-27
- Completion
- 2022-02-27
- First posted
- 2021-02-21
- Last updated
- 2022-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04763226. Inclusion in this directory is not an endorsement.